<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01586364</url>
  </required_header>
  <id_info>
    <org_study_id>15-50312</org_study_id>
    <nct_id>NCT01586364</nct_id>
  </id_info>
  <brief_title>Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus</brief_title>
  <official_title>Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus: A 52-Week Open-Label Follow-Up to Protocol 15-50310</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>QuatRx Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study was to assess the long-term safety of daily doses of ospemifene 60
      mg in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women without a
      uterus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2006</start_date>
  <completion_date type="Actual">December 22, 2008</completion_date>
  <primary_completion_date type="Actual">November 21, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Week 13 (Phone Contact) to Week 56 (Visit 4)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Serum Lipid Levels at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Serum Lipid Levels at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Blood Pressure at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
    <description>Systolic blood pressure (SBP), diastolic blood pressure (DBP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Pulse Rate at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Weight at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Mass Index (BMI) at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Blood Pressure at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Pulse Rate at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Weight at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in BMI at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Visual Evaluation of Vagina at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
    <description>Each of the categories in the table was assessed on a 4-point scale (0=None, 1=Mild, 2=Moderate, 3=Severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Visual Evaluation of Vagina at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
    <description>Each of the categories in the table was assessed on a 4-point scale (0=None, 1=Mild, 2=Moderate, 3=Severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Cervical Pap Smear Samples (if Cervix is Intact)</measure>
    <time_frame>Week 52 (Visit 3)</time_frame>
    <description>Cervical Pap smear samples are used to evaluate: atypical squamous cells of undetermined significance (ASC-US), squamous intraepithelial lesions (SILs), intraepithelial lesions or malignancy, and reactive endocervical cells and/or metaplastic cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Breast Palpation at Visit 2</measure>
    <time_frame>Week 26 (Visit 2)</time_frame>
    <description>Breast palpation was used to assess breast abnormalities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Breast Palpation at Visit 3</measure>
    <time_frame>Week 52 (Visit 3)</time_frame>
    <description>Breast palpation was used to assess breast abnormalities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Coagulation Parameters (Antithrombin Antigen, Protein C Antigen, Protein S Antigen) at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Activated Partial Thromboplastin Time (Plasma) at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Fibrinogen (Plasma) Levels at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Coagulation Parameters (Antithrombin Antigen, Protein C Antigen, Protein S Antigen) at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Activated Partial Thromboplastin Time (Plasma) at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Fibrinogen (Plasma) Levels at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Leukocyte, Lymphocyte, Monocyte and Platelet Count Levels at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Erythrocyte Levels at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin Levels at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematocrit and Red Blood Cell (RBC) Distribution Width at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Leukocyte, Lymphocyte, Monocyte and Platelet Count Levels at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Erythrocyte Levels at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin Levels at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematocrit and RBC Distribution Width at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in MCV and MPV at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Albumin and Total Protein Levels at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Kinase (CK) Levels at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bilirubin, Creatinine, Glucose, Uric Acid and Blood Urea Nitrogen (BUN) Levels at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Albumin and Total Protein Levels at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in ALT, AST and CK Levels at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Bilirubin, Creatinine, Glucose, Uric Acid and BUN Levels at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in pH of Urine at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Specific Gravity of Urine at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in pH of Urine at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Specific Gravity of Urine at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Estradiol (E2) Levels at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Levels at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Sex Hormone Binding Globulin (SHBG) Levels at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Testosterone Levels at Visit 2</measure>
    <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in E2 Levels at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in FSH and LH Levels at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in SHBG Levels at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Testosterone Levels at Visit 3</measure>
    <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">301</enrollment>
  <condition>Atrophy</condition>
  <condition>Vaginal Diseases</condition>
  <arm_group>
    <arm_group_label>Ospemifene 60 mg Oral Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ospemifene 60Mg Oral Tablet</intervention_name>
    <arm_group_label>Ospemifene 60 mg Oral Tablet</arm_group_label>
    <other_name>OsphenaÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women aged 40 to 80 years with a diagnosis of vulvar and vaginal
             atrophy (VVA) as assessed by vaginal pH, maturation index of vaginal smear, and
             self-reported symptoms at Baseline for Protocol 15-50310

          -  Did not have a uterus

          -  Met the inclusion and exclusion criteria for Protocol 15-50310

          -  Had completed Protocol 15-50310 without any clinically significant abnormal findings
             at the end-of-study visit for Protocol 15-50310

          -  Provided written informed consent to participate in the study and agreed to follow
             dosing instructions and complete all required study visits

        Exclusion Criteria:

          -  Had clinically significant abnormal findings at the Week 12 End of Study visit for
             Protocol 15-50310

          -  Had any physical or mental condition which, in the opinion of the investigator, may
             have interfered with the subject's ability to comply with the study procedures
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2012</study_first_posted>
  <results_first_submitted>March 20, 2013</results_first_submitted>
  <results_first_submitted_qc>May 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 28, 2013</results_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menopausal symptoms</keyword>
  <keyword>Vulvar and vaginal atrophy in menopausal women</keyword>
  <keyword>Vaginal atrophy</keyword>
  <keyword>Urogenital atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm = 60 mg Ospemifene</title>
          <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other-Did not feel better post-treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other-Subject wasn't getting much relief</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other-Site closure due to PI illness</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other-PI discretion, site closing</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other-Not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm = 60 mg Ospemifene</title>
          <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="301"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.4" spread="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="301"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="280"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161.90" spread="6.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.54" spread="13.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.865" spread="4.4106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events (AEs)</title>
        <time_frame>Week 13 (Phone Contact) to Week 56 (Visit 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events (AEs)</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment-Emergent AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE (Possibly/Probably/Definitely Related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Causing Study Drug Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Serum Lipid Levels at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, 241 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Lipid Levels at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, 241 out of 301 subjects were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="17.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low-density lipoprotein cholesterol (LDL-C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="29.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-density lipoprotein cholesterol (HDL-C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" spread="16.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.51" spread="43.422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Serum Lipid Levels at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, 195 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Lipid Levels at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, 195 out of 301 subjects were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="16.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="22.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" spread="15.226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.07" spread="43.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Blood Pressure at Visit 2</title>
        <description>Systolic blood pressure (SBP), diastolic blood pressure (DBP)</description>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 244 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure at Visit 2</title>
          <description>Systolic blood pressure (SBP), diastolic blood pressure (DBP)</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 244 out of 301 subjects were analyzed.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="15.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pulse Rate at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 244 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 244 out of 301 subjects were analyzed.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="10.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weight at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 244 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 244 out of 301 subjects were analyzed.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.798" spread="3.6022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Body Mass Index (BMI) at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 244 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Mass Index (BMI) at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 244 out of 301 subjects were analyzed.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.309" spread="1.3628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Blood Pressure at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 199 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 199 out of 301 subjects were analyzed.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="16.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="9.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pulse Rate at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 199 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 199 out of 301 subjects were analyzed.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="9.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weight at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 199 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 199 out of 301 subjects were analyzed.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.122" spread="8.2464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in BMI at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 199 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in BMI at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 199 out of 301 subjects were analyzed.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.439" spread="3.2779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Visual Evaluation of Vagina at Visit 2</title>
        <description>Each of the categories in the table was assessed on a 4-point scale (0=None, 1=Mild, 2=Moderate, 3=Severe)</description>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Evaluation of Vagina at Visit 2</title>
          <description>Each of the categories in the table was assessed on a 4-point scale (0=None, 1=Mild, 2=Moderate, 3=Severe)</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Petechiae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pallor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal Dryness in Mucosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal Redness in Mucosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Visual Evaluation of Vagina at Visit 3</title>
        <description>Each of the categories in the table was assessed on a 4-point scale (0=None, 1=Mild, 2=Moderate, 3=Severe)</description>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 198 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Evaluation of Vagina at Visit 3</title>
          <description>Each of the categories in the table was assessed on a 4-point scale (0=None, 1=Mild, 2=Moderate, 3=Severe)</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 198 out of 301 subjects were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Petechiae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pallor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal Dryness in Mucosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal Redness in Mucosa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Cervical Pap Smear Samples (if Cervix is Intact)</title>
        <description>Cervical Pap smear samples are used to evaluate: atypical squamous cells of undetermined significance (ASC-US), squamous intraepithelial lesions (SILs), intraepithelial lesions or malignancy, and reactive endocervical cells and/or metaplastic cells.</description>
        <time_frame>Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 16 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Cervical Pap Smear Samples (if Cervix is Intact)</title>
          <description>Cervical Pap smear samples are used to evaluate: atypical squamous cells of undetermined significance (ASC-US), squamous intraepithelial lesions (SILs), intraepithelial lesions or malignancy, and reactive endocervical cells and/or metaplastic cells.</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 16 out of 301 subjects were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Atypical Squamous Cells-Undetermined Significance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative for Intraepithelial Lesion or Malignancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Breast Palpation at Visit 2</title>
        <description>Breast palpation was used to assess breast abnormalities.</description>
        <time_frame>Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Breast Palpation at Visit 2</title>
          <description>Breast palpation was used to assess breast abnormalities.</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Breast Palpation at Visit 3</title>
        <description>Breast palpation was used to assess breast abnormalities.</description>
        <time_frame>Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 199 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Breast Palpation at Visit 3</title>
          <description>Breast palpation was used to assess breast abnormalities.</description>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 199 out of 301 subjects were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Coagulation Parameters (Antithrombin Antigen, Protein C Antigen, Protein S Antigen) at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 242 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Coagulation Parameters (Antithrombin Antigen, Protein C Antigen, Protein S Antigen) at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 242 out of 301 subjects were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Antithrombin Antigen, Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein C Antigen, Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="21.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein S Antigen, Free, Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="15.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Activated Partial Thromboplastin Time (Plasma) at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 242 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Activated Partial Thromboplastin Time (Plasma) at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 242 out of 301 subjects were analyzed.</population>
          <units>s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="14.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Fibrinogen (Plasma) Levels at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 242 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fibrinogen (Plasma) Levels at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 242 out of 301 subjects were analyzed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.4" spread="80.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Coagulation Parameters (Antithrombin Antigen, Protein C Antigen, Protein S Antigen) at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 194 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Coagulation Parameters (Antithrombin Antigen, Protein C Antigen, Protein S Antigen) at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 194 out of 301 subjects were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Antithrombin Antigen, Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="10.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein C Antigen, Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="22.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein S Antigen, Free, Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="20.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Activated Partial Thromboplastin Time (Plasma) at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 194 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Activated Partial Thromboplastin Time (Plasma) at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 194 out of 301 subjects were analyzed.</population>
          <units>s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="17.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Fibrinogen (Plasma) Levels at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 194 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fibrinogen (Plasma) Levels at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 194 out of 301 subjects were analyzed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.9" spread="77.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Leukocyte, Lymphocyte, Monocyte and Platelet Count Levels at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 240 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Leukocyte, Lymphocyte, Monocyte and Platelet Count Levels at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 240 out of 301 subjects were analyzed.</population>
          <units>(x10(9)/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="1.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.058" spread="0.4025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.012" spread="0.1557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="41.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Erythrocyte Levels at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 240 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Erythrocyte Levels at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 240 out of 301 subjects were analyzed.</population>
          <units>(x10(12)/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.098" spread="0.2454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin Levels at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 240 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin Levels at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 240 out of 301 subjects were analyzed.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematocrit and Red Blood Cell (RBC) Distribution Width at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 240 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematocrit and Red Blood Cell (RBC) Distribution Width at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 240 out of 301 subjects were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="2.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC distribution width</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 240 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 240 out of 301 subjects were analyzed.</population>
          <units>fL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCV, free</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="1.732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Leukocyte, Lymphocyte, Monocyte and Platelet Count Levels at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Leukocyte, Lymphocyte, Monocyte and Platelet Count Levels at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
          <units>(x10(9)/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="1.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" spread="0.4410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.021" spread="0.1619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.5" spread="36.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Erythrocyte Levels at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Erythrocyte Levels at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
          <units>(x10(12)/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.108" spread="0.2745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin Levels at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin Levels at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematocrit and RBC Distribution Width at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematocrit and RBC Distribution Width at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="2.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC distribution width</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in MCV and MPV at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MCV and MPV at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
          <units>fL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCV, free</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="2.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MPV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Albumin and Total Protein Levels at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Albumin and Total Protein Levels at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Kinase (CK) Levels at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Kinase (CK) Levels at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="10.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="5.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="46.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Bilirubin, Creatinine, Glucose, Uric Acid and Blood Urea Nitrogen (BUN) Levels at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bilirubin, Creatinine, Glucose, Uric Acid and Blood Urea Nitrogen (BUN) Levels at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin Total, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Plasma/Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Plasma/Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="17.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Albumin and Total Protein Levels at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 197 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Albumin and Total Protein Levels at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 197 out of 301 subjects were analyzed.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in ALT, AST and CK Levels at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 197 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ALT, AST and CK Levels at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 197 out of 301 subjects were analyzed.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="11.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="109.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Bilirubin, Creatinine, Glucose, Uric Acid and BUN Levels at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 197 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Bilirubin, Creatinine, Glucose, Uric Acid and BUN Levels at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 197 out of 301 subjects were analyzed.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin Total, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Plasma/Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Plasma/Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="16.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid, Serum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in pH of Urine at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 239 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in pH of Urine at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 239 out of 301 subjects were analyzed.</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="1.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Specific Gravity of Urine at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 239 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Specific Gravity of Urine at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 239 out of 301 subjects were analyzed.</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0003" spread="0.00672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in pH of Urine at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 195 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in pH of Urine at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 195 out of 301 subjects were analyzed.</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="1.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Specific Gravity of Urine at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 195 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Specific Gravity of Urine at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 195 out of 301 subjects were analyzed.</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0010" spread="0.00695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Estradiol (E2) Levels at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estradiol (E2) Levels at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Levels at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Levels at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FSH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="14.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Sex Hormone Binding Globulin (SHBG) Levels at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sex Hormone Binding Globulin (SHBG) Levels at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="22.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Testosterone Levels at Visit 2</title>
        <time_frame>Baseline to Week 26 (Visit 2)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Testosterone Levels at Visit 2</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 26, 243 out of 301 subjects were analyzed.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone, Free</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Testosterone, Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="5.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in E2 Levels at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in E2 Levels at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in FSH and LH Levels at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FSH and LH Levels at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FSH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.9" spread="13.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="6.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in SHBG Levels at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SHBG Levels at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" spread="23.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Testosterone Levels at Visit 3</title>
        <time_frame>Baseline to Week 52 (Visit 3)</time_frame>
        <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm = 60 mg Ospemifene</title>
            <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Testosterone Levels at Visit 3</title>
          <population>The ITT population was used for the analysis. For this particular outcome measure, at week 52, 196 out of 301 subjects were analyzed.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone, Free</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Testosterone, Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="5.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>56 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm = 60 mg Ospemifene</title>
          <description>Subjects took an oral dose of Ospemifene 60 mg tablet each morning with food for 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intentional Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Spinal Meningioma Benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrahagic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis Superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shionogi Clinical Trials Administrator</name_or_title>
      <organization>Shionogi Inc.</organization>
      <phone>800-849-9707 ext 1454</phone>
      <email>shionogiclintrialsadmin@shionogi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

